TABLE 1.
Antibiotic susceptibility rates, MIC50, and MIC90 for the 150 XDR P. aeruginosa isolates studied
| Antibiotica | MIC50 (mg/liter) | MIC90 (mg/liter) | CLSI guidelinesb |
EUCAST guidelinesb |
||
|---|---|---|---|---|---|---|
| % S | % R | % S | % R | |||
| TIC | 256 | >512 | 0.0 | 94.0 | 0.0 | 100.0 |
| PIP/TZ | 128 | 256 | 1.3 | 80.0 | 1.3 | 98.7 |
| CAZ | 32 | >64 | 2.0 | 80.7 | 2.0 | 98.0 |
| FEP | 32 | >64 | 3.3 | 60.0 | 3.3 | 96.7 |
| TOL/TZ | 4 | >64 | 68.7 | 20.7 | 68.7 | 31.3 |
| ATM | 16 | 64 | 16.7 | 41.3 | 0.0 | 41.3 |
| IMI | 32 | >64 | 0.0 | 100.0 | 0.0 | 98.7 |
| MER | 16 | >64 | 0.0 | 99.3 | 0.0 | 86.0 |
| CIP | >16 | >16 | 1.3 | 97.3 | 1.3 | 98.7 |
| TOB | 32 | >32 | 22.7 | 74.7 | 22.7 | 77.3 |
| AMI | 4 | 16 | 92.7 | 4.0 | 86.0 | 7.3 |
| COL | 2 | 2 | 97.3 | 2.7 | 97.3 | 2.7 |
a
TIC, ticarcillin; PIP/TZ, piperacillin-tazobactam; CAZ, ceftazidime; FEP, cefepime; TOL/TZ, ceftolozane-tazobactam; ATM, aztreonam; IMI, imipenem; MER, meropenem; CIP, ciprofloxacin; TOB, tobramycin; AMI, amikacin; COL, colistin.
b
S, susceptible; R, resistant.